![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage industrial firm centered on creating significant improvements in immuno-dermatology, in the present day introduced that it’s going to host a convention name and webcast at 5:00 p.m. ET on Tuesday, November 8, 2022, to report its third quarter monetary outcomes.
The schedule for the press launch and convention name/webcast is as follows:
- Q3 2022 Press Release: Tuesday, November 8, 2022, after the shut of the U.S. monetary markets
- Q3 2022 Earnings Call: Tuesday, November 8, 2022, at 5:00 p.m. ET
A dwell webcast of the decision and the presentation materials will likely be accessible on the “Events” part of the Company’s investor web site. An archived replay of the webcast will likely be accessible on the Arcutis investor web site following the convention.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology firm that champions significant innovation to deal with the pressing wants of people dwelling with immune-mediated dermatological ailments and situations. With a dedication to fixing probably the most persistent affected person challenges in dermatology, Arcutis harnesses our distinctive dermatology improvement platform coupled with our dermatology experience to construct differentiated therapies towards biologically validated targets. Arcutis’ dermatology improvement platform features a sturdy pipeline with a number of medical packages for a spread of inflammatory dermatological situations together with scalp psoriasis, atopic dermatitis, and seborrheic dermatitis. For extra data, go to www.arcutis.com or observe Arcutis on LinkedIn, Facebook, and Twitter.
Forward-Looking Statements
This press launch comprises “forward-looking” statements. These statements contain substantial identified and unknown dangers, uncertainties and different elements that will trigger our precise outcomes, ranges of exercise, efficiency, or achievements to be materially totally different from the data expressed or implied by these forward-looking statements and you shouldn’t place undue reliance on our forward-looking statements. Risks and uncertainties that will trigger our precise outcomes to differ embrace dangers inherent within the medical improvement course of and regulatory approval course of, the timing of regulatory filings, and our capability to defend our mental property. For an additional description of the dangers and uncertainties relevant to our business, see the “Risk Factors” part of our Form 10-Okay filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as amended on March 3, 2022, in addition to any subsequent filings with the SEC. We undertake no obligation to revise or replace data herein to mirror occasions or circumstances sooner or later, even when new data turns into accessible.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
[email protected]
Investors
Eric McIntyre, Head of Investor Relations
[email protected]
